Posted On: 06/16/2016 8:00:28 PM
Post# of 99118
$EBIO new climber $2.57
Website
Shares Outstanding: 19.88M
Float: 4.78M
% Held by Insiders: 12.73%
% Held by Institutions: 73.60%
Shares Short (as of May 31, 2016): 1.29M
Short Ratio (as of May 31, 2016): 0.40
Short % of Float (as of May 31, 2016): 11.61%
Shares Short (prior month): 1.25M
Headlines
Eleven Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company develops its therapeutics through AMP-Rx, a proprietary protein engineering platform. Its lead product candidate is EBI-005, which has completed Phase III clinical trials for the treatment of patients with dry eye disease and allergic conjunctivitis. The company is also developing EBI-031 that is in preclinical development to treat diabetic macular edema; and a product candidate as an intravitreal injection for the treatment of certain retinal diseases, such as wet age-related macular degeneration. Eleven Biotherapeutics, Inc. has a collaboration and license agreement with ThromboGenics N.V. to identify protein or peptide therapeutics that directly modulate any of a specified set of targets in a novel pathway in retinal disease. The company was founded in 2008 and is based in Cambridge,
Website
Shares Outstanding: 19.88M
Float: 4.78M
% Held by Insiders: 12.73%
% Held by Institutions: 73.60%
Shares Short (as of May 31, 2016): 1.29M
Short Ratio (as of May 31, 2016): 0.40
Short % of Float (as of May 31, 2016): 11.61%
Shares Short (prior month): 1.25M
Headlines
Eleven Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company develops its therapeutics through AMP-Rx, a proprietary protein engineering platform. Its lead product candidate is EBI-005, which has completed Phase III clinical trials for the treatment of patients with dry eye disease and allergic conjunctivitis. The company is also developing EBI-031 that is in preclinical development to treat diabetic macular edema; and a product candidate as an intravitreal injection for the treatment of certain retinal diseases, such as wet age-related macular degeneration. Eleven Biotherapeutics, Inc. has a collaboration and license agreement with ThromboGenics N.V. to identify protein or peptide therapeutics that directly modulate any of a specified set of targets in a novel pathway in retinal disease. The company was founded in 2008 and is based in Cambridge,
(0)
(0)
